Tuesday January 28, 2020

New Biomarker Helps Identify Cancer Chemotherapy Timing

Angiogenesis therapy is clinically used to suppress tumour growth. Adding an anti-angiogenic drug can boost an anticancer drug's effectiveness

0
//
Biomarker can be used to decide timing fro chemotherapy.

In ray of hope for doctors to identify the tumour normalising period for effective timing of anti-cancer drug treatment, a team of researchers have discovered a new biomarker that can visualise the activity of blood vessels.

Angiogenesis, the formation of new blood vessels, is essential for tumour growth. The team from Osaka University in Japan, in a paper reported in The American Journal of Pathology, described a vascular stabilization biomarker that can visualize blood vessel activity, thus optimising the timing of anticancer therapies including anti-angiogenics.

Chronic diseases are not yet included in cancer prevention schemes.
This can help cancer patients greatly.

Combination therapy using angiogenesis inhibitors and anticancer drugs can improve drug delivery into tumour tissues and prolong progression-free survival. “Vascular normalisation by angiogenesis inhibitors, such as vascular endothelial growth factor (VEGF) signaling inhibitors, is a promising method for improvement of chemotherapy.

“However, it is unclear how we can recognise the ‘window of opportunity’ for the tumour vascular normalising period for effective timing of anti-cancer drug treatment. Therefore, biomarkers delineating this window are essential,” explained Nobuyuki Takakura, Professor at Research Institute for Microbial Diseases, Osaka University.

Also Read: What We Know About Cancer Risk and Coffee

Angiogenesis therapy is clinically used to suppress tumour growth. Adding an anti-angiogenic drug can boost an anticancer drug’s effectiveness. Basic research indicates that anti-angiogenic therapy allows the blood vessels to return to quiescence and “normalise” so that the anti-cancer drug can penetrate the tumour more effectively. IANS

Next Story

Patients May Suffer Invasive Treatments for Harmless Cancers: Researchers

According to the researchers, It is the first time that the risk of overdiagnosis has been quantified across five cancers, anywhere in the world

0
A breast cancer diagnosis is terrifying enough at any time. Pixabay

Researchers have revealed that Australians are increasingly being diagnosed with potentially harmless cancers, which if left undetected or untreated, may expose them to unnecessary surgeries and chemotherapy.

The research, published in the Medical Journal of Australia, drew on data from the Australian Institute of Health and Welfare to compare how the lifetime risk of five cancers had changed between 1982 and 2012.

The study shows compared to 30 years ago, Australians are much more likely to experience a cancer diagnosis in their lifetime.

“Cancer treatments such as surgery, radiotherapy, endocrine and chemotherapy carry risks of physical harms,” said the study authors from Bond University, University of Sydney and Griffith University in Australia.

“In the absence of overdiagnosis, these harms are generally considered acceptable. In the context of overdiagnosed cancers, however, affected individuals cannot benefit but can only be harmed by these treatments,” authors added.

The figures suggest that in 2012 24 per cent of cancers or carcinomas in men were overdiagnosed. These included 42 per cent of prostate cancers, 42 per cent of renal cancers, 73 per cent of thyroid cancers and 58 per cent of melanomas.

Cancer
Cancer Ribbon. Pixabay

For women, 18 per cent of cancers or carcinomas were overdiagnosed, including 22 per cent of breast cancers, 58 per cent of renal cancers, 73 per cent of thyroid cancers and 58 per cent of melanomas.

The figures are significant because of the harm that can occur from cancer treatment of patients who would never have had symptoms in their lifetime.

The authors also refer to separate studies showing overdiagnosis could be linked to psychological problems.

“For example, men’s risk of suicide appears to increase in the year after receiving a prostate cancer diagnosis,” researchers said.

Also Read: TikTok Becomes a Rising Phenomenon in India

According to the researchers, It is the first time that the risk of overdiagnosis has been quantified across five cancers, anywhere in the world.”

The findings also suggest an important role for health services such as the Australian Institute of Health and Welfare, in detecting potential overdiagnosis and alerting health policy decision makers to the problem early on. (IANS)